Form SC 13G Sarepta Therapeutics, Filed by: FMR LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair
February 9, 2018 11:51 AM ESTWilliam Blair analyst Tim Lugo came out to deafened Sarepta Therapeutics (NASDAQ: SRPT) following reports of a U.K.-specific hold on further dosing of patients enrolled in Sareptas global Phase III ESSENCE trial of golodirsen.
Lugo sees the concerns as "overblown".
To wit... "We see todays roughly 6% sell-off... More



